CD33 and acute myeloid leukemia: A subsequent phase I clinical trial confirmed the consideration of safety infusing irradiated CD33 CAR-NK-92 cells in three patients with relapsed or refractory AML, although nothing noteworthy therapeutic efficacy was noted (151).